Sanofi

2Q Revenues: $11.2 billion (flat)

2Q Earnings: $1.5 billion (flat)

YTD Revenues: $21.9 billion (-6%)

YTD Earnings: $3.9 billion (+15%)

Comments: Pharmaceutical sales were flat at $9.4 billion. Sales lost to generic competition were $205.0 million in the quarter (Lovenox, Xatral and Taxotere in the U.S., and Taxotere, Plavix and Aprovel in the EU). Eloxatin sales were up 36% to $471.6 million. Diabetes revenue was up 14% driven by Lantus sales, up 17% to $1.5 billion. Vaccines sales were $984.7 million in the quarter, up 3%. Genzyme sales (Cerezyme, Myozyme, Fabrazyme, and Other Rare Disease products) were $545.8 million, up 9%. Emerging Markets sales were $3.5 billion, up 10%.